Safety and Efficacy Study of Absnow Absorbable ASD Closure System For Treating ASD Patients
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03601039|
Recruitment Status : Recruiting
First Posted : July 26, 2018
Last Update Posted : July 26, 2018
|Condition or disease||Intervention/treatment||Phase|
|Heart Septal Defects, Atrial Atrial Septal Defect||Device: Absnow Absorbable ASD Closure System||Not Applicable|
Atrial Septal Defect (hereinafter referred to as "ASD") is a common congenital heart disease (hereinafter referred to as "CHD"), accounting for about 10% of CHD in children.Initially，ASD was treated by surgical operation. Nowdays transcatheter ASD closure, characterized by minimal invasion, definite curative effect, short recovery period, and no need for cardiopulmonary bypass, provides a new safe and effective therapy for CHD. According to a large number of clinical reports, the use of transcatheter closure devices for ASD closure has a high success rate, good closure effect and low risk of complications.
Absnow absorbable ASD closure system has undergone implantation experiments that implant it into animal (pig) ASD models, with the implantation success rate being 100%. Up to 2 years' observation indicated that the cardiomyocytes and endothelial cells covering the implanted device were not different from those of the control group (nickel-titanium alloy occluder) and were of a great number, and the inflammatory response was remarkably lower than that of the control group. During the observation period, all occluders in the trial did not fall off or were displaced, no evident postoperative complications and therefore, this occluder has the feasibility of local application and system safety.
Absnow absorbable ASD closure system developed by LifeTech Scientific passed the registration inspection of CFDA Shenzhen Medical Device Quality Monitoring and Inspection Center, verifying that this closure system conforms to the product technical specification in mechanical strength, physiochemical properties and biological properties. According to the provisions in Measures for Administration of Medical Device Registration (No. 4 Order) and Regulation on Quality Management of Medical Device Clinical Trial (No. 25) issued by CFDA, this product has the conditions for clinical trial.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||144 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Evaluation of Safety and Efficacy of the Absnow Absorbable ASD Closure System For Treating ASD Patients|
|Estimated Study Start Date :||August 1, 2018|
|Estimated Primary Completion Date :||March 31, 2024|
|Estimated Study Completion Date :||June 30, 2024|
Experimental: Absnow Absorbable ASD Closure System
All subjects are implanted with Absnow Absorbable ASD Occluder
Device: Absnow Absorbable ASD Closure System
the eligible subjects who meet the inclusion criteria should sign the ICF before operation (-30 to 0 day), then receive the Absnow absorbable ASD Closure System implantation. The follow-up time will be set as observation point : the next day after operation, 30-day post-operative , 90-day post-operative, 180-day post-operative, 360-day post-operative, 2 year post-operative, 3 year post-operative, 4 year post-operative and 5 year post-operative. If any AE/SAE occurs during clinical trial, the subjects should be observed till such AE/SAE disappear or stable.
- The successful rate at 30-day post ASD closure operative,which meaning that the TTE or TEE observation shows that residual shunt ＜5mm at 30-days postoperative. [ Time Frame: 30-day post ASD closure operative ]The successful rate at 30-day post ASD closure operative,which meaning that the TTE or TEE observation shows that residual shunt ＜5mm at 30-days postoperative.
- The rate of severe complication during 360-day post ASD closure operative [ Time Frame: 360-day post ASD closure operative ]The rate of severe complication during 360-day post ASD closure operative. The severe complication includes all-cause mortality,coronary artery aeroembolism ,cardiac tamponade ,thromboembolism ,occluder dislodgment,repeated migraine, migraine,occluder displacement,mitral regurgitation,heart or aortic root perforation, high degree atrioventricular block and moderate to large residual shunt.
- immediate operation success rates [ Time Frame: immediate postoperative ]the occluder is successfully implanted which means left and right disks are effectively fixed on left and right sides of atrial septum, respectively and smoothly released without displacement or falling off and the delivery system and the delivery system is successfully withdrawn.
- Device-related AE (adverse event) rates [ Time Frame: 5 years post operation ]AE refers to adverse medical events occurring during clinical trial no matter if they are device-related
- Device-related SAE (serious adverse event) rates [ Time Frame: 5 years post operation ]SAE refers to events occurring in the clinical trial that can lead to death or serious health deterioration, including fatal disease or injure, permanent defects of body structure or function, need for hospitalization or prolonging hospitalization time or medial or operation intervention to avoid permanent defects of body structure or body function, fetal distress, fetal death or congenital anomaly, congenital defects.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03601039
|Contact: Xie Yumei, MDfirstname.lastname@example.org|
|Pan Xiangbin||Not yet recruiting|
|Beijing, Beijing, China|
|Contact: Pan Xiangbin|
|Yi Kaijian||Not yet recruiting|
|Chongqing, Chongqing, China|
|Contact: Yi Kaijian|
|Guangzhou, Guangdong, China|
|Contact: Zhang Zhiwei|
|Yu Bo||Not yet recruiting|
|Harbin, Heilongjiang, China|
|Contact: Yu Bo|
|Fan Taibing||Not yet recruiting|
|Zhenzhou, Henan, China|
|Contact: Fan Taibing|
|Fang Zhenfei||Not yet recruiting|
|Changsha, Hunan, China|
|Contact: Fang Zhenfei|
|Kong Xiangqing||Not yet recruiting|
|Nanjing, Jiangsu, China|
|Contact: Kong Xiangqing|
|Chen Sun||Not yet recruiting|
|Shanghai, Shanghai, China|
|Contact: Chen Sun|
|Li Fei||Not yet recruiting|
|Shanghai, Shanghai, China|
|Contact: Li Fei|
|Liu Cong||Not yet recruiting|
|Shenzhen, Shenzhen, China|
|Contact: Liu Cong|
|Gong Fangqi||Not yet recruiting|
|Hangzhou, Zhejiang, China|
|Contact: Gong Fangqi|